Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit

Leukemia and Lymphoma

Volumn 51, Issue 5, 2010, Pages 846-852

  Katsibardi, Katerina ^a   Moschovi, Maria A ^a   Braoudaki, Maria ^a   Papadhimitriou, Stefanos I ^b   Papathanasiou, Chrissa ^a   Tzortzatou Stathopoulou, Fotini ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

ALL; Childhood; Chromosomal abnormalities; Minimal residual disease; PCR; TEL AML1

Indexed keywords

BCR ABL PROTEIN; CD135 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; MIXED LINEAGE LEUKEMIA PROTEIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILD; CHROMOSOME ABERRATION; EVENT FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS;

BONE MARROW; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; COHORT STUDIES; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT, GAMMA-CHAIN T-CELL ANTIGEN RECEPTOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS;

EID: 77951787638     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003682734     Document Type: Article

References (35)

1. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-1218.
2. Pui CH, Sandlund JT, Pei D, et al. Total Therapy Study XIIIB at St Jude Children's Research Hospital. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004;104:2690-2696.
3. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia-current status and future perspectives. Lancet Oncol 2001;2:597-607.
4. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85:1416-1434.
5. Szczepański T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007;21:622-626.
6. Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 2005;90:382-390.
7. Szczepański T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukemia. Best Pract Res Clin Haematol 2002;15:37-57.
8. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 2000;14:783-785.
9. Béné MC, Kaeda JS. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European Leukemia Net. Hematologica 2009;94:1135-1150.
10. Bennett JM, Catovsky D, Daniel MT, et al. The morphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlations. Br J Haematol 1981;47:553-561.
11. Tzortzatou-Stathopoulou F, Moschovi MA, Papadopoulou AL, et al. Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors? Eur J Haematol 2005;75:361-369.
12. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia? Leukemia 1999;13:110-118.
13. Meleshko AN, Lipay NV, Stasevich IV, Potapnev MP. Rearrangements of IgH, TCRD and TCRG genes as clonality marker of childhood acute lymphoblastic leukemia. Exp Oncol 2005;27:319-324.
14. Yokota S, Hansen-Hagge TE, Ludwig WD, et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 1991;77:331-339.
15. Botsonis T, Tsangaris GT, Mikraki V, Tzortzatou-Stathopoulou F. Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes. Anticancer Res 1999;19:2211-2220.
16. Braoudaki M, Karpusas M, Katsibardi K, Papathanassiou C, Karamolegou K, Tzortzatou-Stathopoulou F. Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia. Med Oncol 2008 Dec. 16. [Epub ahead of print]
17. van der Velden VH, Szczepanski T, Wijkhuijs JM, et al. Agerelated patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia 2003;17:1834-1844.
18. Dawidowska M, Derwich K, Szczepański T, et al. Pattern of immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Polish pediatric acute lymphoblastic leukemia patients-implications for RQ-PCR-based assessment of minimal residual disease. Leuk Res 2006;30:1119-1125.
19. Cole-Sinclair M, Foroni L, Wright F, Mehta A, Prentice HG, Hoffbrand AV. Minimal residual disease in acute lymphoblastic leukemia-PCR analysis of immunoglobulin gene rearrangements. Leuk Lymphoma 1993;11:49-58.
20. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, von dem Borne AE, van der Schoot CE. Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia. Blood 1993;82:581-589.
21. van der Velden VH, Boeckx N, van Wering ER, van Dongen JJ. Detection of minimal residual disease in acute leukemia. J Biol Regul Homeost Agents 2004;18:146-54.
22. Zhou J, Goldwasser MA, Li A, et al. Dana-Farber Cancer Institute ALL Consortium. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007;110:1607-1611.
23. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691-2696.
24. Scrideli CA, Queiroz RG, Bernardes JE, Valera ET, Tone LG. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification. Med Pediatr Oncol 2003;41:10-16.
25. Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002;20:1094-1104.
26. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997;336:317-323.
27. Marshall GM, Haber M, Kwan E, et al. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:704-709.
28. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 1998;352:1731-1738.
29. Martínez-Ramírez A, Urioste M, Contra T, et al. Fluorescence in situ hybridization study of TEL/AML1 fusion and other abnormalities involving TEL and AML1 genes. Correlation with cytogenetic findings and prognostic value in children with acute lymphocytic leukemia. Haematologica 2001;86:1245-1253.
30. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion gene in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. Blood 1997;90:571-577.
31. Liang DC, Chou TB, Chen JS, et al. High incidence of TEL/AML1 fusion resulting from a cryptic t (12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan. Leukemia 1996;10:991-993.
32. Park KU, She CJ, Shin HY, et al. Low incidence of TEL/AML1 fusion and TEL deletion in Korean childhood acute leukemia by extra-signal fluorescence in situ hybridization. Cancer Genet Cytogenet 2001;126:73-77.
33. Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006;107:4508-4513.
34. Woo HY, Kim DW, Park H, Seong KW, Koo HH, Kim SH. Molecular cytogenetic analysis of gene rearrangements in childhood acute lymphoblastic leukemia. J Korean Med Sci 2005;20:36-41.
35. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997;90:4933-4937.